PMID- 36192500 OWN - NLM STAT- MEDLINE DCOM- 20221005 LR - 20221201 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 12 IP - 1 DP - 2022 Oct 3 TI - The relationship between systemic immune inflammation index and survival in patients with metastatic renal cell carcinomatreated withtyrosine kinase inhibitors. PG - 16559 LID - 10.1038/s41598-022-20056-3 [doi] LID - 16559 AB - This study aims to investigate the prognostic value of the systemic immune-inflammation index (SII)and its impact on survival in patients with metastatic renal cell carcinoma (mRCC). A total of 706patients with mRCC treated with tyrosine kinase inhibitors (TKIs)between January 2007 and June 2020 (i.e., sunitinib, pazopanib) were included in this study. SII was calculated in 621 patients with the following formula:[neutrophil (cellsx10(9)/L) x platelet (cellsx10(9)/L)] / lymphocyte (cellsx10(9)/L).All patients were classified into SII-high and SII-low groups based on the cut-off value of SII at 756, which was the median SII level of our study group. The minimal follow-up duration was 10 months in all cohorts. The median age of patients was 60 (interquartile range (IQR):53-67) years. Three out of four patients were male. The majority of patients (85.7%) had clear cell histology, and sarcomatoid differentiation was observed in 16.9% of all patients. There were 311 and 310 patients in the SII-low and SII-high groups, respectively. In general, baseline characteristics were similar in each group. However, the rate of patients treated with sunitinib (63.3% vs. 49.0%, p < 0.001) and those who underwent nephrectomy (83.6% vs. 64.2%, p < 0.001) was higher in the SII-low group than in the SII-high group. On the other hand, patients with the IMDC poorrisk (31.6% vs. 8.0%, p < 0.001), those with bone (51.8% vs. 32.2%, p < 0.001) or central nervous system (12.9% vs. 5.8%, p = 0.026) metastasis, and those with Eastern Cooperative Oncology Group(ECOG) 2-4 performance score (28.1% vs.17.7%, p = 0.002) were more common in the SII-high group than in the SII-low group. The median overall survival (OS) was longer in the SII-low group than in the SII-high group (34.6 months vs. 14.5 months, p < 0.001). Similarly, the median progression-free survival (PFS) was longer in the SII-low group than in the SII-high group (18.0 months vs. 7.7 months, p < 0.001).In multivariableanalysis, SII was an independent prognostic factor for OS (hazard ratio (HR):1.39, 95% confidence interval (CI):1.05-1.85, p = 0.01) and PFS (HR:1.60, 95% CI:1.24-2.05, p < 0.001).Pre-treatment level of high SII might be considered a predictor of poor prognosisin patients with mRCC treated with TKIs. CI - (c) 2022. The Author(s). FAU - Yucel, Kadriye Bir AU - Yucel KB AD - Department of Internal Medicine, Faculty of Medicine, Ankara University, Ankara, Turkey. FAU - Yekeduz, Emre AU - Yekeduz E AD - Department of Medical Oncology, Faculty of Medicine, Cebeci Hospital, Ankara University, 06590, Cebeci/Ankara, Turkey. AD - Cancer Research Institute, Ankara University, Ankara, Turkey. FAU - Karakaya, Serdar AU - Karakaya S AD - Medical Oncology Department, Dr. Abdurrahman Yurtaslan Ankara Oncology Education and Research Hospital, University of Health Sciences, Ankara, Turkey. FAU - Tural, Deniz AU - Tural D AD - Department of Medical Oncology, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, University of Health Sciences, Istanbul, Turkey. FAU - Erturk, Ismail AU - Erturk I AD - Department of Medical Oncology, Gulhane Education and Research Hospital, University of Health Sciences, Ankara, Turkey. FAU - Erol, Cihan AU - Erol C AD - Department of Medical Oncology, Faculty of Medicine, Ankara Yildirim Beyazit University, Ankara, Turkey. FAU - Ercelep, Ozlem AU - Ercelep O AD - Department of Medical Oncology, Faculty of Medicine, Marmara University, Istanbul, Turkey. FAU - Oztas, Nihan Senturk AU - Oztas NS AD - Division of Medical Oncology, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey. FAU - Arslan, Cagatay AU - Arslan C AD - Department of Medical Oncology, Faculty of Medicine, Izmir University of Economics, Izmir, Turkey. FAU - Ucar, Gokhan AU - Ucar G AD - Department of Medical Oncology, Ankara City Hospital, University of Health Sciences, Ankara, Turkey. FAU - Kucukarda, Ahmet AU - Kucukarda A AD - Department of Medical Oncology, Faculty of Medicine, Trakya University, Edirne, Turkey. FAU - Sever, Ozlem Nuray AU - Sever ON AD - Department of Medical Oncology, Faculty of Medicine, Gaziantep University, Gaziantep, Turkey. FAU - Kilickap, Saadettin AU - Kilickap S AD - Department of Medical Oncology, Faculty of Medicine, Hacettepe University, Ankara, Turkey. AD - Department of Medical Oncology, Faculty of Medicine, Istinye University, Istanbul, Turkey. FAU - Can, Orcun AU - Can O AD - Department of Medical Oncology, Prof. Dr. Cemil Tascioglu City Hospital, University of Health Sciences, Istanbul, Turkey. FAU - Yazgan, Sati Coskun AU - Yazgan SC AD - Department of Internal Medicine, Faculty of Medicine, Ankara University, Ankara, Turkey. FAU - Oksuzoglu, Berna AU - Oksuzoglu B AD - Medical Oncology Department, Dr. Abdurrahman Yurtaslan Ankara Oncology Education and Research Hospital, University of Health Sciences, Ankara, Turkey. FAU - Karadurmus, Nuri AU - Karadurmus N AD - Department of Medical Oncology, Gulhane Education and Research Hospital, University of Health Sciences, Ankara, Turkey. FAU - Sendur, Mehmet Ali AU - Sendur MA AD - Department of Medical Oncology, Faculty of Medicine, Ankara Yildirim Beyazit University, Ankara, Turkey. FAU - Urun, Yuksel AU - Urun Y AD - Department of Medical Oncology, Faculty of Medicine, Cebeci Hospital, Ankara University, 06590, Cebeci/Ankara, Turkey. yuksel.urun@ankara.edu.tr. AD - Cancer Research Institute, Ankara University, Ankara, Turkey. yuksel.urun@ankara.edu.tr. LA - eng PT - Journal Article DEP - 20221003 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 RN - 0 (Protein Kinase Inhibitors) RN - V99T50803M (Sunitinib) SB - IM MH - *Carcinoma, Renal Cell/pathology MH - Female MH - Humans MH - Inflammation MH - *Kidney Neoplasms/pathology MH - Male MH - Prognosis MH - Protein Kinase Inhibitors/therapeutic use MH - Retrospective Studies MH - Sunitinib/therapeutic use PMC - PMC9529965 COIS- The authors declare no competing interests. EDAT- 2022/10/04 06:00 MHDA- 2022/10/06 06:00 PMCR- 2022/10/03 CRDT- 2022/10/03 23:26 PHST- 2021/11/21 00:00 [received] PHST- 2022/09/08 00:00 [accepted] PHST- 2022/10/03 23:26 [entrez] PHST- 2022/10/04 06:00 [pubmed] PHST- 2022/10/06 06:00 [medline] PHST- 2022/10/03 00:00 [pmc-release] AID - 10.1038/s41598-022-20056-3 [pii] AID - 20056 [pii] AID - 10.1038/s41598-022-20056-3 [doi] PST - epublish SO - Sci Rep. 2022 Oct 3;12(1):16559. doi: 10.1038/s41598-022-20056-3.